Proceedings of the 25th BCTRIMS Annual Meeting

Introduction: Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating disease of central nervous system associated with neurodegeneration. Regarding treatment and epidemiological data about MS, there is a lack of scientific studies in Brazil and Latin America, mainly as to the formulation of treatment protocols, as well as better strategies of clinical and diagnostic evaluation; mainly in progressive forms. Objective: To evaluate the disability profile of patients followed with progressive MS at a hospital in northeast of Brazil. Methods: This was a retrospective cohort, which evaluates the disability profile of patients followed with progressive MS and associations with treatment, between the years of 2020 to 2024. The disability profile was assessed by the Expanded Disability Status Scale from the analysis of medical records, along with available clinical-epidemiological data, using the BRANDO platform, a database developed by the Brazilian and the Latin American committee for studies in MS, for data collection. along with available clinical-epidemiological data. Also, we analyzed the association between disability, clinical and disease modifying therapy (DMT). Results 42 patients with PMS diagnosis were included, of which 26 (61.9%) were female. Median EDSS was of 6.5 (range 1.5-9.5), in line with the impairment at labor activities observed in this cohort, as 34 (80.9%) patients were reported as retired or unemployed due to MS. Age was correlated with greater disability, while no significant difference was observed between the samples as to the disease progression and DMT’s use. Conclusion: Significant disability and high work impairment were observed in the population with PMS analyzed. Older age was the only factor correlated with higher EDSS values ​​in our sample. New studies will be necessary to better evaluate the patients’ disability profile, including a complete approach and more broad functional tests in a systematic way to better monitor the patient and evaluate therapeutic response.